SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours

被引：2
|
作者：
Baselga, J. [1 ]
Cortes Castan, J. [2 ,3 ]
De Laurentiis, M. [4 ]
Dieras, V. [5 ]
Harbeck, N. [6 ]
Hsu, J. [7 ]
Jin, H. [8 ]
Schimmoller, F.
Wilson, T. R. [9 ]
Im, Y-H. [10 ]
Jacot, W. [11 ]
Krop, I. E. [12 ]
Verma, S. [13 ]
机构：
[1] Mem Hosp, Mem Sloan Kettering Canc Ctr, Dept Med, Human Oncol & Pathogenesis Program HOPP, New York, NY USA
[2] Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain
[3] Ramon & Cajal Univ Hosp, Madrid, Spain
[4] Fdn G Pascale, Ist Nazl Tumori, Breast Oncol Dept, Naples, Italy
[5] Inst Curie, Dept Med Oncol, Paris, France
[6] Univ Munich, Breast Canc Ctr, Munich, Germany
[7] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[8] Genentech Inc, Dept Oncol, San Francisco, CA 94080 USA
[9] Genentech Inc, Oncol Biomarker Dept, San Francisco, CA 94080 USA
[10] Samsung Med Ctr, Dept Med, Seoul, South Korea
[11] Inst Canc Montpellier ICM, Dept Med Oncol, Montpellier, France
[12] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[13] Univ Calgary, Dept Oncol, Tom Baker Canc Ctr, Calgary, AB, Canada
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw365.92
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
313TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [11] PEGGY: A phase II randomised study of the PI3-kinase (PI3K) inhibitor pictilisib (GDC-0941) plus paclitaxel in patients (pts) with hormone receptor (HR)-positive, HER2-negative locally recurrent or metastatic breast cancer (mBC)
    Vuylsteke, P.
    Huizing, M.
    Petrakova, K.
    Roylance, R.
    Laing, R.
    Chan, S.
    Abell, F.
    Apt, D.
    Zhou, J.
    Singel, S.
    Fehrenbacher, L.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S265 - S266
  • [12] PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer.
    Pascual, Javier
    MacPherson, Iain R.
    Armstrong, Anne Caroline
    Ward, Sarah Emily
    Parmar, Mona
    Turner, Alison Joanne
    Bye, Hannah
    Proszek, Paula
    Dodson, Andrew
    Garcia-Murillas, Isaac
    King, Jenny
    Hall, Emma
    Finneran, Laura
    Lopez, Juanita Suzanne
    Okines, Alicia Frances Clare
    Ring, Alistair E.
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [13] Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer
    Moein, Anita
    Jin, Jin Y.
    Wright, Matthew R.
    Wong, Harvey
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (03) : 421 - 436
  • [14] Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
    Dickler, Maura N.
    Saura, Cristina
    Richards, Donald A.
    Krop, Ian E.
    Cervantes, Andres
    Bedard, Philippe L.
    Patel, Manish R.
    Pusztai, Lajos
    Oliveira, Mafalda
    Cardenas, Alison K.
    Cui, Na
    Wilson, Timothy R.
    Stout, Thomas J.
    Wei, Michael C.
    Hsu, Jerry Y.
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2018, 24 (18) : 4380 - 4387
  • [15] Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) plus fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)
    Turner, N.
    Jhaveri, K.
    Kalinsky, K.
    Loibl, S.
    Loi, S.
    Im, S-A.
    Saura, C.
    Schmid, P.
    Schutzman, J. L.
    Stout, T.
    Lei, G.
    Hutchinson, K. E.
    Thanopoulou, E.
    Juric, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S391 - S392
  • [16] Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer
    Saura, Cristina
    Sachdev, Jasgit
    Patel, Manish R.
    Cervantes, Andres
    Juric, Dejan
    Infante, Jeffrey R.
    Richards, Donald
    Sanabria, Sandra
    Lu, Xuyang
    Ware, Joseph
    Wilson, Timothy R.
    Parmar, Hema
    Hsu, Jerry Y.
    Oliveira, Mafalda
    Winer, Eric P.
    Von Hoff, Daniel D.
    Baselga, Jose
    Krop, Ian E.
    CANCER RESEARCH, 2015, 75
  • [17] Ph1b study of the PI3K inhibitor GDC-0032 in combination with fulvestrant in patients with hormone receptor-positive advanced breast cancer
    Juric, D.
    Saura, C.
    Cervantes, A.
    Kurkjian, C.
    Patel, M. R.
    Sachdev, J.
    Mayer, I.
    Krop, I. E.
    Oliveira, M.
    Sanabria, S.
    Cheeti, S.
    Lin, R. S.
    Graham, R. A.
    Wilson, T. R.
    Parmar, H.
    Hsu, J. Y.
    Von Hoff, D. D.
    Baselga, J.
    CANCER RESEARCH, 2013, 73
  • [18] Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA
    Dickler, M. N.
    Saura, C.
    Oliveira, M.
    Richards, D. A.
    Krop, I. E.
    Cervantes, A.
    Stout, T. J.
    Jin, H.
    Savage, H. M.
    Wilson, T. R.
    Baselga, J.
    CANCER RESEARCH, 2017, 77
  • [19] A phase I/Ib study evaluating GDC-0077+palbociclib (palbo) plus fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
    Bedard, Philippe L.
    Jhaveri, Komal
    Cervantes, Andres
    Gambardella, Valentina
    Hamilton, Erika
    Italiano, Antoine
    Kalinsky, Kevin
    Krop, Ian E.
    Oliveira, Mafalda
    Saura, Cristina
    Schmid, Peter
    Turner, Nicolas
    Varga, Andrea
    Hutchinson, Katherine E.
    Lei, Guiyuan
    Royer-Joo, Stephanie
    Thomas, Piia
    Schutzman, Jennifer L.
    Juric, Dejan
    CANCER RESEARCH, 2021, 81 (04)
  • [20] Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) plus fulvestrant (F) in patients with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)
    Turner, Nicolas
    Jhaveri, Komal
    Kalinsky, Kevin
    Loibl, Sibylle
    Loi, Sherene
    Im, Seock-Ah
    Saura, Cristina
    Schmid, Peter
    Schutzman, Jennifer L.
    Stout, Thomas J.
    Lei, Guiyuan
    Hutchinson, Katherine E.
    Thanopoulou, Eirini
    Juric, Dejan
    CANCER RESEARCH, 2021, 81 (04)
12345